Jessica Moody, LCSW in Youngsville, LA - Social Worker

Jessica Moody, LCSW is a Social Worker - Clinical based in Youngsville, Louisiana. Jessica Moody is licensed to practice in Louisiana (license number 12621) and her current practice location is 100 Sabal Palms Row Ste 1, Youngsville, Louisiana. She can be reached at her office (for appointments etc.) via phone at (337) 306-4565.

NPI number for Jessica Moody is 1942828561 and her current mailing address is Po Box 1296, Youngsville, Louisiana. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1942828561.

Contact Information

	Jessica Moody, LCSW
	100 Sabal Palms Row Ste 1, Youngsville, LA 70592-6754
	(337) 306-4565
	Not Available

Healthcare Provider's Profile

Full Name	Jessica Moody
Gender	Female
Speciality	Social Worker - Clinical
Location	100 Sabal Palms Row Ste 1, Youngsville, Louisiana
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1942828561
Provider Enumeration Date: 07/09/2020
Last Update Date: 10/01/2023

Medical Identifiers

Medical identifiers for Jessica Moody such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942828561	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	12621 (Louisiana)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jessica Moody is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jessica Moody, LCSW Po Box 1296, Youngsville, LA 70592-1296 Ph: (337) 303-7109	Jessica Moody, LCSW 100 Sabal Palms Row Ste 1, Youngsville, LA 70592-6754 Ph: (337) 306-4565

News Archive

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

Chloride-restrictive intravenous strategy may decrease incidence of AKI among critically ill patients

In a pilot study assessing the effect of different levels of chloride in intravenous fluids administered to critically ill patients in an intensive care unit, restricting the amount of chloride administration was associated with a significant decrease in the incidence of acute kidney injury and the use of renal replacement therapy, according to a study in the October 17 issue of JAMA.

Support for health law remains steady while opposition drops

"The percentage of people who view the new health bill unfavorably dropped 6 points to 35 percent in the past month, but that has not translated into a significant increase of supporters, according to the July tracking poll from the Kaiser Family Foundation. Overall support remained stable since the June survey, with about half the public expressing a favorable view of the overhaul, the poll found" (Verdon, 7/29).

Texas scientist says nonmedical community should be educated about long-term effects of antibiotic overuse and misuse

When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

Social Worker in Youngsville, LA

Erin Lovett, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2445 E Milton Ave, Youngsville, LA 70592 Phone: 337-277-4675
Myra B Gulotta, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 237 Forest Grove Dr, Youngsville, LA 70592 Phone: 337-577-5203
Katherine Broussard Juneau, LCSW, BACS Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 317 Nora Broussard Rd, Youngsville, LA 70592 Phone: 337-789-4689 Fax: 337-789-4689

Jessica Moody, LCSW - Clinical Social Worker in Youngsville, LA